Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in Saudi Arabia has been experiencing significant growth in recent years.
Customer preferences: Customers in Saudi Arabia have a strong preference for branded drugs over generic alternatives. This is due to the belief that branded drugs are of higher quality and more effective. Additionally, there is a strong demand for over-the-counter (OTC) drugs, particularly for common ailments such as headaches and colds.
Trends in the market: The Saudi Arabian pharmaceuticals market has been growing at a steady pace in recent years, driven by a number of factors. One of the key drivers of growth has been the increasing prevalence of chronic diseases, such as diabetes and hypertension, which has led to increased demand for pharmaceuticals. Additionally, the government has been investing heavily in the healthcare sector, which has helped to boost the pharmaceuticals market. There has also been a trend towards the development of more specialized drugs, particularly in areas such as oncology and rare diseases.
Local special circumstances: One of the key challenges facing the pharmaceuticals market in Saudi Arabia is the regulatory environment. The Saudi Food and Drug Authority (SFDA) has strict regulations in place for the approval and registration of drugs, which can make it difficult for companies to bring new products to market. Additionally, there is a lack of transparency in the regulatory process, which can be a barrier to entry for smaller companies.
Underlying macroeconomic factors: The Saudi Arabian pharmaceuticals market is closely tied to the overall health of the economy. As the economy continues to grow, there is likely to be increased demand for pharmaceuticals, particularly in areas such as chronic disease management. Additionally, the government's continued investment in the healthcare sector is expected to drive further growth in the market. However, the ongoing COVID-19 pandemic has had a significant impact on the healthcare sector, and it remains to be seen how this will affect the pharmaceuticals market in the long term.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)